Compassionate use of quinacrine in Creutzfeldt–Jakob disease fails to show significant effects

@article{Hak2004CompassionateUO,
  title={Compassionate use of quinacrine in Creutzfeldt–Jakob disease fails to show significant effects},
  author={St{\'e}phane Ha{\"i}k and Jean-Philippe Brandel and Dominique Salomon and V. Sazdovitch and Nicole Delasnerie‐Laupr{\^e}tre and Jean-Louis Laplanche and Baptiste Faucheux and Claudine Soubri{\'e} and E Boher and Chantal B{\'e}lorgey and Jean Jacques Hauw and Annick Alp{\'e}rovitch},
  journal={Neurology},
  year={2004},
  volume={63},
  pages={2413 - 2415}
}
Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt–Jakob disease (CJD). The authors report the results of an open compassionate procedure to which 32 CJD patients had access. In some genotypic subgroups, a slight but nonsignificant increase in survival was observed, likely due to biased inclusion of long-term surviving patients. There was no pathologic evidence of a beneficial effect of quinacrine treatment. 
Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial
TLDR
Doxycycline at a dose of 100 mg per day was well tolerated but did not significantly affect the course of CJD, at variance with the results of previous observational studies.
Clinical aspects of variant Creutzfeldt-Jakob disease.
TLDR
There are uncertainties about the future because of many unknowns, including the length and distribution of the incubation period, the extent of the species barrier to transmission between bovines and humans, the level and temporal distribution of dietary human exposure to bovine spongiform encephalopathy (BSE), and the impact of secondary transmission of vCJD through blood transfusion or other routes.
Sporadic Creutzfeldt-Jakob disease.
TLDR
By showing that these disease subtypes correspond to specific agent strain-host genotype combinations, recent transmission studies have confirmed the biologic basis of this classification and significantly contributed to the improved accuracy of the clinical diagnosis of sporadic CJD.
Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial
TLDR
Quinacrine at a dose of 300 mg per day was reasonably tolerated but did not significantly affect the clinical course of prion diseases in this observational study.
Doxycycline in early CJD: a double-blinded randomised phase II and observational study
TLDR
A larger trial of doxycycline should be performed in persons in the earliest stages of CJD, as a slight increase in survival time in the doxy cycline treatment group was observed.
Therapies for prion diseases.
TLDR
The clinicians might face several specific problems when evaluating the efficacy of the drug in CJD, such as rareness of the disease, lack of appropriate preclinical tests and heterogeneous clinical presentation in humans, which have to be carefully addressed in future.
Toward Therapy of Human Prion Diseases.
TLDR
The attempts to interfere with the replication of prions and to enhance their clearance are discussed and some of the possibilities to identify novel targets that may arise with increasing insights into prion biology are traced.
Antiprion Activity of DB772 and Related Monothiophene- and Furan-Based Analogs in a Persistently Infected Ovine Microglia Culture System
TLDR
Results suggest that a potential target for inhibition at biologically relevant concentrations is through PrPC misfolding to PrPSc, and structure-activity relationship analysis suggests that two structural elements were associated with micromolar antiprion activity.
Discovering new treatments for Alzheimer's disease by repurposing approved medications.
TLDR
The current data suggest several compounds worthy of further study as treatments for AD, and several compounds with the highest scores include lithium, minocycline, exenatide, valproic acid, methylene blue, and nicotine.
2,4-diarylthiazole antiprion compounds as a novel structural class of antimalarial leads.
TLDR
All but one of the compounds displayed activity against a chloroquine-resistant Plasmodium falciparum strain, identifying them as interesting leads for further development in this context and three new members of the series showed superior antiprion activity compared to the earlier-reported compounds.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 12 REFERENCES
Quinacrine does not prolong survival in a murine Creutzfeldt‐Jakob disease model
TLDR
This work studied the utility of quinacrine in a well‐characterized in vivo model of mouse‐adapted transmissible spongiform encephalopathy and failed to show any evidence that qu inacrine is effective when using the simple but objective measure of survival prolongation.
Combined quinacrine and chlorpromazine therapy in fatal familial insomnia.
TLDR
2 fatal familial insomnia patients whose overall condition worsened despite quinacrine and chlorpromazine treatment are reported on.
Drugs for malaria and psychosis may offer hope to people with CJD
Doctors at the University of California in San Francisco are starting clinical trials for Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD) with quinacrine and chlorpromazine, after finding that
Diagnosis of Creutzfeldt-Jakob disease
TLDR
Detection of the 14-3-3 protein in CSF, considered as an additional diagnostic criterion for clinically probable CJD, resulted in a slight increase in the estimated incidence when the French or European study criteria were applied.
Evaluation of Quinacrine Treatment for Prion Diseases
TLDR
Despite its ability to cross the blood-brain barrier, the use of quinacrine for the treatment of CJD is questionable, at least as a monotherapy, and the multistep experimental approach employed here could be used to test new therapeutic regimes before their use in human trials.
Treatment of Transmissible Spongiform Encephalopathy by Intraventricular Drug Infusion in Animal Models
TLDR
It is indicated that intraventricular PPS infusion might be useful for the treatment of transmissible spongiform encephalopathies in humans, providing that the therapeutic dosage is carefully evaluated.
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease
TLDR
It is reported here that tricyclic derivatives of acridine and phenothiazine exhibit half-maximal inhibition of PrPSc formation at effective concentrations (EC50) between 0.3 μM and 3 μM in cultured cells chronically infected with prions.
Neuropathologic variants of sporadic Creutzfeldt–Jakob disease and codon 129 of PrP gene
TLDR
Polymorphism at codon 129 modulates the phenotype of sporadic Creutzfeldt–Jakob disease and enhances the production of proteinase-resistant PrP, and the Met/Val genotype facilitates its aggregation into amyloid plaques.
Lysosomotropic Agents and Cysteine Protease Inhibitors Inhibit Scrapie-Associated Prion Protein Accumulation
We report that lysosomotropic agents and cysteine protease inhibitors inhibited protease-resistant prion protein accumulation in scrapie-infected neuroblastoma cells. The inhibition occurred without
...
1
2
...